Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study)

Hepatitis C Virus Infection Clinical Trial

Official title:

Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00399672
• Other study ID #: C06-0192
• Status: Completed
• Phase: N/A
• First received: November 14, 2006
• Last updated: November 28, 2016
• Start date: June 2007
• Est. completion date: December 2012

Study information

• Verified date: November 2016
• Source: University of British Columbia
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

Although injection drug users (IDUs) account for over 70% of new cases of HCV infection/year, there is no consensus on how to approach their medical care. In some Canadian centres, patients must be free of recreational drug use for as long as 6 months before being considered for HCV therapy. This is not consistent with current North American guidelines. Over the past 5 years, we have developed a successful program for the treatment of HIV infection in this population, based on a multi-disciplinary comprehensive program including directly observed therapy (DOT). Even though the duration of therapy for HCV is shorter than for HIV (as little as 6 months vs. life-long), we must address issues of administration of a weekly injection (interferon), twice daily pills (ribavirin) and the risk of significant side effects (including anxiety and depression) to successfully expand our program to treat this disease. Further, it may be that even if the program is successful, its benefits will be negated by HCV re-infection due to continued risk behaviors for its transmission.

Description:

We will determine the HCV infection status of potential study subjects within a cohort of 2,000 IDUs receiving care in our centres (Appendix 1). For those who carry HCV antibodies (expected n = 1800), a test for HCV viremia and genotype will be performed. By these evaluations, we expect up to 600 individuals to be viremic and carry HCV genotype 2 or 3. Within this group, 200 consecutive patients (100/study strategy) will receive therapy for HCV, based on their eligibility to do so according to Provincial guidelines for the reimbursement of medications. Patient allocation will be according to the study site where they regularly receive care. At two sites, patients will be enrolled in a DOT program with on-site full-time nursing and counseling support (high intensity, 50 patients/site). At the other two sites, patients will receive medication on a weekly basis and will have access to part-time nursing and counseling support (low intensity, 50 patients/site). Medical follow-up will be according to current clinical standards, and the primary endpoint of the study will be the rate of sustained virologic response (SVR) six months after completion of treatment. Within the study described above, we will use standardized methodologies to calculate the total health care costs related to the treatment of HCV infection. We will also assess the effect of treatment on the quality of life (QoL) of study participants.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 370
• Est. completion date: December 2012
• Est. primary completion date: August 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Age > 19 years;

• Serum HCV-RNA pos;

• HCV genotype 2 or 3;

• HBsAg neg;

• serum ALT > 1.5x upper limit normal > 3 months;

• Illicit drug use in the past year;

• Agreement from each participant of childbearing age to practice contraception;

• Absence of other contraindications to the initiation of therapy as determined by the health care team;

• Ability to provide informed consent.

Exclusion Criteria:

• Any cause for chronic liver disease other than HCV (including alcohol use >350 g/wk);

• Pregnant or breastfeeding women;

• Active HBV infection;

• Hemolytic anemia;

• Decompensated cirrhosis or portal hypertension or PT-INR > 1.3 or Child-Hugh class > A;

• Active suicidal ideation, psychosis, mania or hypomania;

• Serum creatinine > 180 µg/mL;

• Hemoglobin < 120 g/L in men or 110 g/L in women;

• Platelets < 90 x 109/L;

• Neutrophils < 1.5 x 109/L;

• Active autoimmune disease;

• NYHA disease > grade 2;

• Psoriasis requiring systemic therapy;

• Active malignancy apart from non melanoma skin cancer;

• Use of systemic immunosuppressant agents;

• Prior treatment of HCV with interferon or ribavirin;

• HIV positive with CD4 count <300 cells/mm3 or receiving didanosine (due to interaction with ribavirin);

• Life expectancy < 2 years.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis C
• Hepatitis C Virus Infection
• Virus Diseases

Intervention

Drug:
• Interferon injections and ribavirin
Weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
• Interferon injections and ribavirin
Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.

Locations

Country	Name	City	State
Canada	Pender Community Health Centre	Vancouver	British Columbia

Sponsors (2)

Lead Sponsor	Collaborator
University of British Columbia	Canadian Institutes of Health Research (CIHR)

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of sustained virologic response (SVR) six months after completion of treatment.		Unspecified	No
Secondary	Adherence to therapy		Unspecified	No
Secondary	Cost		Unspecified	No
Secondary	Quality of life		Unspecified	No